Patheon Secures Industry Veterans for Senior Sales & Marketing Leadership Roles
Company Appoints Tom Sellig as Senior Vice President Global Sales and Christopher Tama as Senior Vice President Global Marketing
Patheon, the pharmaceutical services business owned by DPx Holdings B.V., today announced it has appointed Tom Sellig as senior vice president, global sales and Christopher Tama as senior vice president of global marketing. These appointments are another critical step in Patheon’s ongoing sales and marketing strategic effort to drive customer growth.
Sellig’s knowledge of corporate strategic account and sales management, customer relationship management, and business partnerships regarding life science products and services will support the company’s growth strategy throughout North America, Europe and Asia. Tama will be responsible for developing high-impact marketing strategies that will generate sales leads for the global pharmaceutical manufacturing company.
“We are pleased to have Tom and Chris join our team,” said Mike Lehmann, president, global pharmaceutical development services and executive vice president, global sales and marketing. “Tom brings more than 25 years of experience, has a reputation for results and effective leadership, and Chris is known for his ability to build customer-centric strategies that drive growth and capture market share. They have each achieved remarkable results throughout their careers in the pharmaceutical and healthcare sectors.”
Most recently, Sellig led the global clinical and market access sales and client service teams at Covance. Prior to his work at Covance, he gained a variety of experience through leadership roles at Ventana Clinical, Digitas Healthcare, Wyeth Consumer, and Procter and Gamble.
Tama joins Patheon from PAREXEL International, Inc., where he transformed Marketing to be a key competitive differentiator for PAREXEL. Prior to joining PAREXEL, Tama served as unit president at Ogilvy CommonHealth and held marketing and sales leadership positions at Novartis and Pfizer.
Tel: (919) 210-0986
About DPx Holdings B.V.
DPx Holdings B.V. is parent company of the Patheon, DPx Fine Chemicals and Banner Life Sciences businesses. The company offers customers unsurpassed quality, end-to-end solutions and value through its three business units. DPx Holdings is a leading provider of CDMO services, pharmaceutical products and other formulated products for various industries. The company was formed in 2014 as a result of the merger of Patheon and DSM Pharmaceutical Products and is owned by JLL Partners and Royal DSM. With a global headquarters in Durham, N.C., DPx Holdings B.V. has a footprint of more than 20 locations across North America, Europe, Latin America and Australia with more than 8,000 employees. For more information, visit www.patheon.com/DPx.
Patheon® is a leading provider of contract development and commercial manufacturing (CDMO) services to the global pharmaceutical industry for a full array of solid and sterile dosage forms, including small molecule API and biologic drug substances. Patheon, a business unit of DPx Holdings B.V., encompasses the combined commercial manufacturing capabilities and pharmaceutical product development services, as well as offers a full array of biologic services and pharmaceutical active pharmaceutical ingredients (API) development. Patheon is #1 in product development services, #2 in commercial scale product manufacturing and is #1 in quality. For more information, visit http://www.patheon.com.